Ji-Hong Pan1, Jin-Xiang Han, Jian-Mei Wu, Hai-Nan Huang, Qing-Zhong Yu, Li-Jun Sheng. 1. Key Laboratory of the Ministry of Public Health for Biotech-Drug, Key Laboratory for Modern Medicine and Technology of Shandong Province, Shandong Medicinal and Biotechnology Center, Shandong Academy of Medical Sciences, Jinan, China. pjh933@yahoo.com.cn
Abstract
BACKGROUND: The multidrug resistance gene 1 (MDR1) encodes P-glycoprotein (P-gp), which plays an important role in mediating multidrug resistance to chemotherapeutic agents. MDR1 gene polymorphisms may have an impact on the expression and function of P-gp, thereby influencing the response to chemotherapy. OBJECTIVES: To investigate whether the MDR1 2677 and 3435 genotypes are associated with the sensitivity of non-small-cell lung cancer (NSCLC) to docetaxel. METHODS: In this study we investigated the potential association of MDR1 2677G>T at exon 21, 3435C>T at exon 26 and their haplotypes with chemotherapy response of 54 Han Chinese patients with NSCLC. The patients were treated with docetaxel-cisplatin. RESULTS: The 2677 GG genotype was associated with a significantly better response to chemotherapy compared with the combined 2677 GT and TT genotype (p = 0.035). The 3435 CC genotype was also associated with a better response to chemotherapy compared with the combined 3435 CT and TT genotypes although the difference was not statistically significant (p = 0.123). Moreover, patients harboring the 2677G-3435C haplotype had a statistically significant better response to chemotherapy compared with those with the other haplotypes combined (p = 0.015). CONCLUSION: Our findings suggest that the MDR1 2677G>T/A polymorphism and the 2677G-3435C haplotype are predictors of treatment response to docetaxel-cisplatin chemotherapy in NSCLC patients. Copyright 2008 S. Karger AG, Basel.
BACKGROUND: The multidrug resistance gene 1 (MDR1) encodes P-glycoprotein (P-gp), which plays an important role in mediating multidrug resistance to chemotherapeutic agents. MDR1 gene polymorphisms may have an impact on the expression and function of P-gp, thereby influencing the response to chemotherapy. OBJECTIVES: To investigate whether the MDR1 2677 and 3435 genotypes are associated with the sensitivity of non-small-cell lung cancer (NSCLC) to docetaxel. METHODS: In this study we investigated the potential association of MDR1 2677G>T at exon 21, 3435C>T at exon 26 and their haplotypes with chemotherapy response of 54 Han Chinese patients with NSCLC. The patients were treated with docetaxel-cisplatin. RESULTS: The 2677 GG genotype was associated with a significantly better response to chemotherapy compared with the combined 2677 GT and TT genotype (p = 0.035). The 3435 CC genotype was also associated with a better response to chemotherapy compared with the combined 3435 CT and TT genotypes although the difference was not statistically significant (p = 0.123). Moreover, patients harboring the 2677G-3435C haplotype had a statistically significant better response to chemotherapy compared with those with the other haplotypes combined (p = 0.015). CONCLUSION: Our findings suggest that the MDR1 2677G>T/A polymorphism and the 2677G-3435C haplotype are predictors of treatment response to docetaxel-cisplatin chemotherapy in NSCLCpatients. Copyright 2008 S. Karger AG, Basel.
Authors: Joel L Weissfeld; Brenda Diergaarde; Tomoko Nukui; Shama Buch; Arjun Pennathur; Mark A Socinski; Jill M Siegfried; Marjorie Romkes Journal: J Thorac Oncol Date: 2014-09 Impact factor: 15.609
Authors: L K Teh; N I Mohamed; M Z Salleh; M Rohaizak; N S Shahrun; J J Saladina; J K S Shia; H Roslan; S Sood; T S Rajoo; S P Muniandy; G Henry; H A Ngow; K T Hla U; J Din Journal: AAPS J Date: 2011-12-20 Impact factor: 4.009
Authors: Anne M Traynor; Ju-Whei Lee; Gerald K Bayer; John M Tate; Sachdev P Thomas; Miroslaw Mazurczak; David L Graham; Jill M Kolesar; Joan H Schiller Journal: Invest New Drugs Date: 2009-02-24 Impact factor: 3.850
Authors: Ilaria Pastina; Elisa Giovannetti; Aldo Chioni; Tristan M Sissung; Francesco Crea; Cinzia Orlandini; Douglas K Price; Claudia Cianci; William D Figg; Sergio Ricci; Romano Danesi Journal: BMC Cancer Date: 2010-09-27 Impact factor: 4.430
Authors: Xia Wen; Christopher J Gibson; Ill Yang; Brian Buckley; Michael J Goedken; Jason R Richardson; Lauren M Aleksunes Journal: Toxicol Sci Date: 2014-07-11 Impact factor: 4.849